Selective progesterone receptor modulators and reproductive health

Area of Science:

• Reproductive endocrinology and pharmacology.
• Drug development and clinical applications.

Background:

• Selective progesterone receptor modulators (SPRMs) and progesterone antagonists are compounds that interact with progesterone receptors.
• While many compounds have been synthesized, few have progressed to clinical testing and commercialization.

Purpose of the Study:

• To review the history, current availability, therapeutic potential, and safety concerns of SPRMs and progesterone antagonists.
• To highlight the existing and potential future applications of these agents in reproductive medicine.

Main Methods:

• This is a review article, synthesizing existing literature on SPRMs and progesterone antagonists.
• The review covers historical development, clinical trial outcomes, and safety data.

Main Results:

• Mifepristone is approved for first-trimester medical abortion and ulipristal acetate for emergency contraception, both generally well-tolerated in single doses.
• Chronic use of these agents has been linked to liver enzyme abnormalities and, rarely, hepatic failure, though causality is not established.
• Significant therapeutic promise exists for SPRMs and progesterone antagonists in treating breast cancer, endometriosis, adenomyosis, and for estrogen-free contraception and cervical ripening.

Conclusions:

• SPRMs and progesterone antagonists offer significant therapeutic potential for various reproductive disorders.
• Further research is needed to fully understand their efficacy and safety profiles for chronic use.
• Exploring alternative formulations, such as local or extended-release options, may mitigate risks of liver function abnormalities.